$3.5 M

U.S. Stem Cell Revenue Q2, 2018
U.S. Stem Cell Gross profit (Q2, 2018)2.5 M
U.S. Stem Cell Gross profit margin (Q2, 2018), %69.7%
U.S. Stem Cell Net income (Q2, 2018)-1.4 M
U.S. Stem Cell EBIT (Q2, 2018)-832.6 K
U.S. Stem Cell Cash, 30-Jun-20181.7 M

U.S. Stem Cell Revenue

U.S. Stem Cell revenue was $5.52 m in FY, 2017

Embed Graph

U.S. Stem Cell Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

96.1 k2.1 m2.2 m3.1 m5.5 m

Revenue growth, %

2040%7%41%

Cost of goods sold

30.8 k844.9 k973 k972 k1.9 m

Gross profit

65.3 k1.2 m1.2 m2.1 m3.6 m

Gross profit Margin, %

68%59%56%68%66%

R&D expense

627 k66.4 k10 k919 6.6 k

General and administrative expense

4.4 m

Operating expense total

627 k66.4 k10 k919 4.4 m

Depreciation and amortization

6.6 k

EBIT

(2.8 m)(3.5 m)(2.6 m)(1.2 m)(804.7 k)

EBIT margin, %

(2947%)(172%)(119%)(38%)(15%)

Interest expense

1.4 m1.6 m1.7 m1.2 m642.1 k

Pre tax profit

(3.1 m)(2.3 m)(1.6 m)(2.1 m)(3.5 m)

Net Income

(3.1 m)(2.3 m)(1.6 m)(2.1 m)(3.5 m)

Quarterly

USDQ1, 2018Q2, 2018

Revenue

1.7 m3.5 m

Cost of goods sold

503.8 k1.1 m

Gross profit

1.2 m2.5 m

Gross profit Margin, %

71%70%

R&D expense

1.3 k3.9 k

General and administrative expense

1.2 m3.3 m

Operating expense total

1.2 m3.3 m

Depreciation and amortization

524 524

EBIT

(9.3 k)(832.6 k)

EBIT margin, %

(1%)(24%)

Interest expense

242.4 k683.4 k

Pre tax profit

(139.2 k)(1.4 m)

Net Income

(139.2 k)(1.4 m)

U.S. Stem Cell Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2017

Cash

46.2 k36.7 k58.4 k986.8 k

Accounts Receivable

43 k

Inventories

70.4 k

Current Assets

66.9 k141.3 k115.6 k1.1 m

PP&E

9.1 k12.7 k14.2 k449.7 k

Total Assets

86.1 k204.8 k229.1 k1.6 m

Accounts Payable

10.2 k

Current Liabilities

13.4 m11.1 m5.7 m6.5 m

Total Liabilities

8.7 m

Additional Paid-in Capital

103.8 m108.9 m114.6 m120.2 m

Retained Earnings

(120.4 m)(122.1 m)(127.6 m)

Total Equity

(13.7 m)(10.9 m)(7.7 m)(7.1 m)

Financial Leverage

0 x0 x0 x-0.2 x

Quarterly

USDQ1, 2018Q2, 2018

Cash

1.7 m1.7 m

Accounts Receivable

75.9 k47.4 k

Inventories

76.7 k66.1 k

Current Assets

1.9 m1.8 m

PP&E

397.6 k345.9 k

Total Assets

2.4 m2.2 m

Accounts Payable

10.2 k10.2 k

Current Liabilities

6.7 m7.2 m

Total Liabilities

8.8 m9.2 m

Additional Paid-in Capital

121 m121.6 m

Retained Earnings

(127.8 m)(129 m)

Total Equity

(6.4 m)(7 m)

Financial Leverage

-0.4 x-0.3 x

U.S. Stem Cell Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.1 m)(2.3 m)(1.6 m)(2.1 m)(3.5 m)

Depreciation and Amortization

2.2 k4.5 k5.3 k5.8 k178.7 k

Accounts Receivable

(43.7 k)

Inventories

(28.1 k)

Accounts Payable

469.2 k

Cash From Operating Activities

(1.9 m)(1.1 m)(844.7 k)1.2 m

Purchases of PP&E

(1.2 k)

Cash From Investing Activities

(9.4 k)(57.8 k)(234 k)723.8 k

Cash From Financing Activities

(1.2 m)

Interest Paid

521.7 k429.6 k321.8 k255.9 k

U.S. Stem Cell Ratios

USDY, 2018

Financial Leverage

-0.3 x
Report incorrect company information